Dr. Steven E. Davis, M.D.
ENT (Otolaryngology) (Otolaryngology Physician)
20911 Earl St, Suite #470
Torrance, CA 90503
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Diego School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 401
Licensed in California since 2001, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of California, San Diego School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngology Physician primary
CA license A75984 (first issued 2001; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Providence Little Company of Mary Med Ctr Torrance Torrance, CA
Medical groups
- Steven E Davis MD Inc (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 401
- Services billed
- 2,913
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 1,053 | 26 |
| Test for allergy using allergenic extract injected into skin | 641 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 382 | 265 |
| Diagnostic exam of nasal passages using an endoscope | 292 | 227 |
| Established patient office or other outpatient visit, 30-39 minutes | 260 | 184 |
| Removal of impacted ear wax | 168 | 134 |
| New patient office or other outpatient visit, 45-59 minutes | 126 | 126 |
| New patient office or other outpatient visit, 30-44 minutes | 114 | 114 |
| Ct scan of face without contrast | 114 | 110 |
| Exam of ear using a microscope | 73 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium Bromide Other prescribers in Torrance, CA | 271 |
| Fluticasone Propionate Other prescribers in Torrance, CA | 95 |
| Azelastine Hcl Other prescribers in Torrance, CA | 52 |
| Mupirocin Other prescribers in Torrance, CA | 34 |
| Omeprazole Other prescribers in Torrance, CA | 29 |
| Xhance (fluticasone propionate) Other prescribers in Torrance, CA | 19 |
| Azelastine-Fluticasone (azelastine/fluticasone) | 18 |
| Famotidine Other prescribers in Torrance, CA | 17 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Torrance, CA | 14 |
| Prednisone Other prescribers in Torrance, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 46 payments worth $7,858 in total to this clinician.
| Spirair, Inc. | $6,057 |
|---|---|
| Aerin Medical Inc. | $928 |
| GlaxoSmithKline, LLC. | $282 |
| Regeneron Healthcare Solutions, Inc. | $193 |
| Genzyme Corporation | $183 |
| Medtronic, Inc. | $62.46 |
| Optinose US, Inc. | $48.28 |
| Neurent Medical Limited | $47.12 |
| Consulting Fee | $5,875 |
|---|---|
| Food and Beverage | $1,839 |
| Education | $116 |
| Travel and Lodging | $27.82 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Spirair, Inc. Apr 4, 2025 | Consulting Fee SEPTALIGN; SEPTALIGN; TURBALIGN · OTOLARYNOLOGY | $5,875 |
| Regeneron Healthcare Solutions, Inc. Aug 4, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $98.34 |
| Aerin Medical Inc. Aug 29, 2025 | Travel and Lodging VIVAER STYLUS · EAR NOSE & THROAT · travel to SAN DEIGO, CA | $27.82 |
| Regeneron Healthcare Solutions, Inc. May 8, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $17.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $181,203 in research payments for these studies, mostly to the institutions running them.
- Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
Spirair, Inc. · Active, not recruiting · NCT06163404 - EFS of Bioabsorbable Implant for NSD
Spirair, Inc. · Completed · NCT05967169 - A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Active, not recruiting · NCT06834347 - Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Paratek Pharmaceuticals, Inc. · Recruiting · NCT06850805 - An interventional efficacy and safety phase 3 doubleblind 2ARM study to investigate orally administered ibuzatrelvir compared with placebo in nonhospitalized symptomatic adult and adolescent participants with COVID19 …
Pfizer Inc. - A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company · Recruiting · NCT06338995 - Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04959448
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.